OTCMKTS:USRM U.S. Stem Cell (USRM) Stock Price, News & Analysis Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume703,100 shsMarket Capitalization$66,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsStock AnalysisChartFinancialsHeadlinesSEC Filings Get U.S. Stem Cell alerts: Email Address Ad Paradigm Press Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.Full details are in this announcement. About U.S. Stem Cell Stock (OTCMKTS:USRM)U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.Read More Ad Paradigm Press Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.Full details are in this announcement. USRM Stock News HeadlinesSeptember 4 at 9:33 AM | msn.comScientists grow blood stem cells in breakthrough that could end need for bone marrow donorsSeptember 3, 2024 | msn.comBlood stem cell breakthrough could have ‘massive impact’ on patientsSeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.September 3, 2024 | msn.comBlood stem cells grown in LAB could end need for bone marrow donorsSeptember 2, 2024 | msn.comBlood stem cells grown in lab for first time in major breakthroughSeptember 2, 2024 | msn.comLab-grown stem cells could be a 'breakthrough' for cancer treatmentAugust 28, 2024 | msn.comNew Stem Cell Therapy Could End Insulin Vigilance for Type 1 Diabetes PatientsAugust 28, 2024 | msn.com'Low-intensity' blood stem cell transplants for sickle cell appear safe for lung healthSeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.August 26, 2024 | washingtonpost.comDiabetes took over her life, until a stem cell therapy freed herAugust 14, 2024 | msn.comScientists discover method to activate dormant stem cells in the brainAugust 9, 2024 | msn.comPotential new approach to enhancing stem-cell transplantsAugust 7, 2024 | msn.comNew stem cell therapy for heart failure undergoing U.S. clinical trialsAugust 7, 2024 | msn.comCancer stem cell-immune cell crosstalk in the tumor microenvironment for liver cancer progressionAugust 5, 2024 | msn.comVitalCells Releases a Breakdown of Cord Blood Banking Flaws Revealed by New York Times, Offering Real Solutions in Stem Cell BankingJuly 31, 2024 | msn.comResearchers elucidate the switch molecule in muscle stem cells that initiates muscle formationJuly 28, 2024 | msn.comU documents stunning impact of poverty on cell function, transplantsJuly 26, 2024 | msn.comDeciphering the journey from stem cells to neurons: Study reveals continuous gene expression changes behind the switchSee More Headlines Receive USRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for U.S. Stem Cell and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2019Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolOTCMKTS:USRM Previous SymbolNASDAQ:BHRT CUSIPN/A CIK1388319 Webwww.us-stemcell.com Phone(954) 835-1500Fax954-845-9976Employees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$80,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / BookN/AMiscellaneous Outstanding Shares661,507,000Free Float550,903,000Market Cap$66,000.00 OptionableNot Optionable Beta-1.31 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Michael Tomas (Age 58)CEO, President, CFO & Director Dr. Colleen RobbSenior Compliance OfficerMr. Phil PosaSenior Vice President of U.S. & International SalesMs. Evelyn FloresCorporate ControllerDr. Sergio PinskiMedical Director & Member of Scientific Advisory BoardKey Competitors(GPCMQ)OTCMKTS:GPCMQWaitrNASDAQ:ASAPCyber Apps WorldOTCMKTS:CYAPCooTek (Cayman)NYSE:CTKNextMartOTCMKTS:NXMRView All Competitors USRM Stock Analysis - Frequently Asked Questions How were U.S. Stem Cell's earnings last quarter? U.S. Stem Cell, Inc. (OTCMKTS:USRM) released its quarterly earnings results on Wednesday, August, 7th. The company reported $0.00 EPS for the quarter. The firm earned $1.30 million during the quarter. How do I buy shares of U.S. Stem Cell? Shares of USRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of U.S. Stem Cell own? Based on aggregate information from My MarketBeat watchlists, some other companies that U.S. Stem Cell investors own include Orion Energy Systems (OESX), Cleveland BioLabs (CBLI), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX) and This page (OTCMKTS:USRM) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding U.S. Stem Cell, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share U.S. Stem Cell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.